Cardiol Therapeutics Inc. CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.43M | 3.47M | 3.79M | 3.92M | 3.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.74M | 7.08M | 5.76M | 7.39M | 5.55M |
| Operating Income | -5.74M | -7.08M | -5.76M | -7.39M | -5.55M |
| Income Before Tax | -4.39M | -7.89M | -5.17M | -7.23M | -6.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.39M | -7.89M | -5.17M | -7.23M | -6.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.39M | -7.89M | -5.17M | -7.23M | -6.04M |
| EBIT | -5.74M | -7.08M | -5.76M | -7.39M | -5.55M |
| EBITDA | -5.73M | -7.07M | -5.75M | -7.38M | -5.53M |
| EPS Basic | -0.04 | -0.07 | -0.05 | -0.09 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.05 | -0.03 | -0.05 | -0.05 |
| EPS Diluted | -0.04 | -0.07 | -0.05 | -0.09 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.05 | -0.03 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 114.94M | 108.99M | 97.94M | 84.73M | 82.65M |
| Average Diluted Shares Outstanding | 114.94M | 108.99M | 97.94M | 84.73M | 82.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |